Glaukos/$GKOS

13:30
21:10
04:45
12:25
20:00
1D1W1MYTD1Y5YMAX

About Glaukos

Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.

Ticker

$GKOS

Primary listing

NYSE

Industry

Health Care Equipment and Supplies

Employees

995

Glaukos Metrics

BasicAdvanced
$5.4B
-
-$2.27
0.88
-

What the Analysts think about Glaukos

Analyst ratings (Buy, Hold, Sell) for Glaukos stock.

Bulls say / Bears say

Glaukos' iStent portfolio has significantly boosted its glaucoma franchise revenues, with the launch of iDose TR in Q2 2024 further enhancing revenue growth. (nasdaq.com)
The company is expanding its international presence, with its international glaucoma franchise recording 17% growth from the comparable period in 2023. (nasdaq.com)
Analysts predict strong adoption of Glaukos' iDose, with a Citigroup survey revealing that 70% of ophthalmologists plan to adopt iDose once available. (wallstreetzen.com)
The FDA denied approval to Glaukos' pre-market approval application for the MicroShunt device, leading to uncertainties about its U.S. commercial launch. (nasdaq.com)
Glaukos faces stiff competition from other medical companies and institutions developing new treatments for glaucoma, which could render its products obsolete. (nasdaq.com)
The company relies on a limited number of third-party suppliers for components of its products; any disruption in supply could adversely affect production. (markets.businessinsider.com)
Data summarised monthly by Lightyear AI. Last updated on 8 Jul 2025.

Glaukos Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Glaukos Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $GKOS

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

No upcoming events
FAQs